Multi-method computational evaluation of the inhibitors against leucine-rich repeat kinase 2 G2019S mutant for Parkinson's disease
Molecular Diversity · 2024
DOI: 10.1007/s11030-024-10808-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diversity, 2024. Verfasst von Ahmed Elhadi und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Bioengineering, Dalian University of Technology, Dalian, 116024, Liaoning, People's Republic of China. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease, Molecular Docking Simulation, Quantitative Structure-Activity Relationship. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben.
Abstract (Originalsprache)
Leucine-rich repeat kinase 2 G2019S mutant (LRRK2 G2019S) is a potential target for Parkinson's disease therapy. In this work, the computational evaluation of the LRRK2 G2019S inhibitors was conducted via a combined approach which contains a preliminary screening of a large database of compounds via similarity and pharmacophore, a secondary selection via structure-based affinity prediction and molecular docking, and a rescoring treatment for the final selection. MD simulations and MM/GBSA calculations were performed to check the agreement between different prediction methods for these inhibitors. 331 experimental ligands were collected, and 170 were used to build the structure-activity relationship. Eight representative ligand structural models were employed in similarity searching and pharmacophore screening over 14 million compounds. The process for selecting proper molecular descriptors provides a successful sample which can be used as a general strategy in QSAR modelling. The rescoring used in this work presents an alternative useful treatment for ranking and selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Bioengineering, Dalian University of Technology, Dalian, 116024, Liaoning, People's Republic of China.
- School of Bioengineering, Dalian University of Technology, Dalian, 116024, Liaoning, People's Republic of China. sjzhong@dlut.edu.cn.
Zitieren
APA
Elhadi, A., Zhao, D., Ali, N., Sun, F., & Zhong, S. (2024). Multi-method computational evaluation of the inhibitors against leucine-rich repeat kinase 2 G2019S mutant for Parkinson's disease. Molecular Diversity. https://doi.org/10.1007/s11030-024-10808-w
Vancouver
Elhadi A, Zhao D, Ali N, Sun F, Zhong S. Multi-method computational evaluation of the inhibitors against leucine-rich repeat kinase 2 G2019S mutant for Parkinson's disease. Molecular Diversity. 2024. doi:10.1007/s11030-024-10808-w
BibTeX
@article{Elhadi2024,
author = {Elhadi, Ahmed and Zhao, Dan and Ali, Noman and Sun, Fusheng and Zhong, Shijun},
title = {Multi-method computational evaluation of the inhibitors against leucine-rich repeat kinase 2 G2019S mutant for Parkinson's disease},
journal = {Molecular Diversity},
year = {2024},
doi = {10.1007/s11030-024-10808-w}
}
EUVIMED